BMO Capital Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $985
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan David Seigerman has maintained an 'Outperform' rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raised the price target from $960 to $985.
August 21, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron Pharmaceuticals' price target has been raised by BMO Capital from $960 to $985, maintaining an 'Outperform' rating.
The raised price target and maintained 'Outperform' rating by BMO Capital indicates a positive outlook for Regeneron Pharmaceuticals. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100